SHP.L - Shire plc

LSE - LSE Delayed Price. Currency in GBp
4,133.50
+30.50 (+0.74%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close4,103.00
Open4,130.00
Bid4,000.50 x 51000
Ask4,150.00 x 53800
Day's Range4,103.50 - 4,144.00
52 Week Range2,940.50 - 4,676.26
Volume1,386,373
Avg. Volume4,870,837
Market Cap37.741B
Beta1.32
PE Ratio (TTM)8.49
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.25 (0.60%)
Ex-Dividend Date2018-03-08
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire3 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire3 days ago

    Shire plc : Block listing Interim Review

    BLOCK LISTING SIX MONTHLY RETURN May 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Name of applicant : Shire plc Name of scheme: Shire Sharesave Scheme Period of return: From: November 23, 2017 To:  May ...

  • GlobeNewswire4 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire4 days ago

    Shire plc : Director Declaration

    Director Declaration May 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Olivier Bohuon, Senior Independent Director of the Company, is to be appointed as a Non-Executive ...

  • GlobeNewswire4 days ago

    Shire announces new hypoparathyroidism data at the 2018 European Congress of Endocrinology

    May 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, presents new data on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) in patients with chronic hypoparathyroidism at the 20th European Congress of Endocrinology (ECE 2018), from 19-22 May 2018, in Barcelona, Spain. The latest studies provide valuable insights into the burden of the disease and impact of treatment in patients with chronic hypoparathyroidism, a rare endocrine disease.

  • GlobeNewswire5 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire6 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire9 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire11 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • PR Newswire11 days ago

    Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness

    LEXINGTON, Mass., May 15, 2018 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces its third annual #FlyforMPS campaign to allow rare champions around the world to recognize and raise awareness for patients and caregivers affected by MPS (mucopolysaccharide) diseases. Shire's #FlyforMPS campaign was created in support of MPS Awareness Day, held annually on May 15th. The campaign was developed in collaboration with the National MPS Society and U.K. MPS Society.

  • GlobeNewswire12 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire16 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire16 days ago

    Caladrius Biosciences Reports 2018 First Quarter Financial Results

    BASKING RIDGE, N.J., May 10, 2018-- Caladrius Biosciences, Inc., a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, ...

  • Business Wire17 days ago

    SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Shire plc And Encourages Investors To Contact The Firm For Additional Information

    The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Shire plc (SHPG) (“Shire” or the “Company”) relating to the proposed buyout of Shire by Takeda Pharmaceutical Company Limited. Under the terms of the agreement, Shire shareholders are anticipated to receive $30.33 in cash and either 0.839 Takeda shares or 1.678 Takeda American Depositary Shares for each share of Shire common stock held.

  • GlobeNewswire18 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Business Wire18 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Shire plc to Takeda Pharmaceutical Company Limited is Fair to Shareholders

    To: All Persons or Entities who purchased Shire plc (“Shire” or the “Company”) (SHPG) stock prior to May 8, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Shire to Takeda Pharmaceutical Company Limited. Under the terms of the transaction, Shire shareholders will receive $30.33 in cash and either 0.839 Takeda shares or 1.678 Takeda American Depositary Shares for each share of Shire they own.

  • Business Wire19 days ago

    Proposed Acquisition of Shire plc by Takeda

    Takeda Pharmaceutical Company Limited (4502.T) (“Takeda”) and Shire plc (SHP.L) (“Shire”) today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire. Under the terms of the acquisition, each Shire shareholder will be entitled to receive $30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.

  • GlobeNewswire19 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • ACCESSWIRE22 days ago

    Blog Exposure - FDA Granted Fast Track Designation for REGENXBIO's RGX-121 Gene Therapy for Mucopolysaccharidosis Type II

    LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on REGENXBIO Inc. (NASDAQ: RGNX) all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RGNX as the Company's latest news hit the wire. On May 2, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for RGX-121, a novel, one-time investigational treatment for Mucopolysaccharidosis Type II (MPS II). Active-Investors.com is currently working on the research report for Shire PLC (NASDAQ: SHPG), which also belongs to the Healthcare sector as the Company REGENXBIO.

  • GlobeNewswire23 days ago

    Shire plc : Rule 2.9 announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire23 days ago

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   May 3, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")   Notification of transactions by person discharging managerial responsibilities   1. Details of ...

  • GlobeNewswire24 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire24 days ago

    Shire plc : Form 8 (DD) - Flemming Ornskov

    FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover ...

  • GlobeNewswire24 days ago

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   May 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG)  Notification of transactions by persons discharging managerial responsibilities   1. Details of the person discharging managerial ...

  • GlobeNewswire24 days ago

    Shire plc : Form 8 (DD) - Thomas Dittrich

    FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover ...